Objectives: To investigate the impact of topiramate versus flunarizine on the non-headache symptoms (NHS) of migraine, and to observe the changes of dopamine (DA) and prolactin (PRL) before and after prophylactic treatment.
Methods: Sixty-six episodic migraine patients were enrolled and randomized 1:1 to receive either flunarizine or topiramate treatment. Clinical characteristics and NHS associated with migraine were investigated before and after prophylactic treatment. The DA and PRL levels were also determined before and after prophylactic treatment.
Results: The NHS of migraine in the two groups were significantly better after treatment than before treatment in premonitory phase (PP), headache phase (HP), and resolution phase (RP). The NHS in the two groups had no significant difference in PP, HP, and RP before and after treatment. In the flunarizine group, the PRL content after treatment was significantly higher than that before treatment ( -4.097, < 0.001), but the DA content was decreased slightly compared with that before treatment ( = 1.909, = 0.066). There was no significant difference in PRL content ( = 1.099, = 0.280) and DA content ( = 1.556, = 0.130) in topiramate group before and after treatment.
Conclusions: The two classical prophylactic drugs of migraine were significantly effective in treating the NHS of migraine, but there was no significant difference between the two drugs. The DA-PRL axis may be involved in the underlying mechanism of the flunarizine treatment for the NHS of migraine.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/00207454.2021.1881091 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of the efficacy and safety of controlled-release phentermine/topiramate in adults with obesity in Korea: A randomized, double-blind, placebo-controlled, phase 4 trial (QUEEN's study).
Diabetes Obes Metab
December 2024
Department of Internal Medicine, Guri Hospital, Hanyang University, College of Medicine, Seoul, Republic of Korea.
Aims: This study evaluated the efficacy and safety of a combination of phentermine and delayed-release topiramate (PHEN/TPM CR) versus placebo as an adjunct to standard lifestyle recommendations in Korean adults.
Materials And Methods: This 56-week, randomized, double-blind, placebo-controlled, phase 4 trial enrolled adults (age 19-70 years) with obesity (BMI ≥ 25 kg/m) at eight sites in South Korea. After a 12-week lifestyle programme, participants were randomly assigned in a 1:1 ratio to receive PHEN/TPM CR or placebo.
A Double-Blind, Placebo-Controlled Study of Adjunctive Topiramate in Adolescents With Co-Occurring Bipolar and Cannabis Use Disorders.
JAACAP Open
December 2024
University of Cincinnati College of Medicine, Cincinnati, Ohio.
Objective: To evaluate the efficacy of adjunctive topiramate (TPM) for the treatment of cannabis use disorder in adolescents with bipolar I disorder.
Method: We conducted a 16-week, double-blind, randomized, placebo-controlled investigation of quetiapine plus TPM (median dose = 208 mg) vs quetiapine plus placebo in adolescents with bipolar I and cannabis use disorder. All subjects participated in a Motivational Interview and Compliance Enhancement Therapy.
2023 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline for the Management of Headache.
Ann Intern Med
December 2024
Aeromedical Consultation Service, U.S. Air Force School of Aerospace Medicine, Wright-Patterson Air Force Base, Ohio; Wright State University Boonshoft School of Medicine, Dayton, Ohio; and Uniformed Services University F. Edward Hebert School of Medicine, Bethesda, Maryland (A.W.F.).
Description: Headache medicine and therapeutics evidence have been rapidly expanding and evolving since the 2020 U.S. Department of Veterans Affairs (VA) and U.
View Article and Find Full Text PDFEfficacy and safety of onabotulinumtoxinA in the treatment of medication overuse headache: a systematic review.
Front Neurol
September 2024
Department of Neurology, West China Hospital of Sichuan University, Chengdu, China.
Article Synopsis
- Medication overuse headache (MOH) is a type of chronic headache caused by frequent use of headache medications, and OnabotulinumtoxinA (BoNTA) is one treatment option, though its effectiveness and safety are debated.
- A systematic search of seven databases found four randomized controlled trials involving 1,259 MOH patients, which revealed that BoNTA significantly decreased headache frequency compared to placebo, but showed no notable differences in other health measures.
- While BoNTA proved effective in reducing headaches, it was associated with a higher rate of adverse events compared to placebo.
Preventive drug treatments for adults with chronic migraine: a systematic review with economic modelling.
Health Technol Assess
October 2024
Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.
Article Synopsis
- Chronic migraine affects 2-4% of adults globally and recent advances in expensive medications have prompted a review of their clinical and cost-effectiveness.
- The study analyzed data from randomised controlled trials involving 7352 adults and compared six different medications, including calcitonin gene-related peptide monoclonal antibodies, Botox, and topiramate, against placebo.
- Results showed that calcitonin gene-related peptide monoclonal antibodies ranked highest in reducing headache days and improving quality of life, while topiramate was less effective compared to these newer treatments.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!